This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagel-Wolfrum, K. Articles by Groner, B. Search for Related Content PubMed PubMed Citation Articles by Nagel-Wolfrum, K. Articles by Groner, B.

---

Signaling and Regulation

The Interaction of Specific Peptide Aptamers With the DNA Binding Domain and the Dimerization Domain of the Transcription Factor Stat3 Inhibits Transactivation and Induces Apoptosis in Tumor Cells¹

¹ Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt am Main, Germany and ² Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany

Requests for reprints: Bernd Groner, Georg-Speyer-Haus, Institute for Biomedical Research, Paul-Ehrlich-Strasse, 42 D-60596 Frankfurt am Main, Germany. Phone: 49-69-63395180; Fax: 49-69-63395185. E-mail: groner{at}em.uni-frankurt.de

The transcription factor signal transducer and activator of transcription (Stat) 3 is activated through the interleukin-6 family of cytokines and by binding of growth factors to the epidermal growth factor (EGF) receptor. It plays an essential role in embryonic development and assumes specialized tasks in many differentiated tissues. Constitutively activated Stat3 has been found in tumor cell lines and primary tumors and plays a crucial role in tumor cell survival and proliferation. To inhibit the oncogenic action of Stat3 in tumor cells, we have selected short peptides, so-called peptide aptamers, which specifically interact with defined functional domains of this transcription factor. The peptide aptamers were selected from a peptide library of high complexity by an adaptation of the yeast two-hybrid procedure. Peptide aptamers specifically interacting with the Stat3 dimerization domain caused inhibition of DNA binding activity and suppression of transactivation by Stat3 in EGF-responsive cells. Similarly, a peptide aptamer selected for its ability to recognize the Stat3 DNA binding domain inhibited DNA binding and transactivation by Stat3 following EGF stimulation of cells. Peptide aptamers were expressed in bacteria as fusion proteins with a protein transduction domain and introduced into human myeloma cells. This resulted in dose-dependent growth inhibition, down-regulation of Bcl-x_L expression, and induction of apoptosis. The inhibition of Stat3 functions through the interaction with peptide aptamers counteracts the transformed phenotype and could become useful in targeted tumor therapy.

This article has been cited by other articles:

				S.-H. Tan and M. T Nevalainen Signal transducer and activator of transcription 5A/B in prostate and breast cancers Endocr. Relat. Cancer, June 1, 2008; 15(2): 367 - 390. [Abstract] [Full Text] [PDF]

				C. Borghouts, C. Kunz, N. Delis, and B. Groner Monomeric Recombinant Peptide Aptamers Are Required for Efficient Intracellular Uptake and Target Inhibition Mol. Cancer Res., February 1, 2008; 6(2): 267 - 281. [Abstract] [Full Text] [PDF]

				S. Kreis, G. A. Munz, S. Haan, P. C. Heinrich, and I. Behrmann Cell Density Dependent Increase of Constitutive Signal Transducers and Activators of Transcription 3 Activity in Melanoma Cells Is Mediated by Janus Kinases Mol. Cancer Res., December 1, 2007; 5(12): 1331 - 1341. [Abstract] [Full Text] [PDF]

				K. Siddiquee, S. Zhang, W. C. Guida, M. A. Blaskovich, B. Greedy, H. R. Lawrence, M. L. R. Yip, R. Jove, M. M. McLaughlin, N. J. Lawrence, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity PNAS, May 1, 2007; 104(18): 7391 - 7396. [Abstract] [Full Text] [PDF]

				C. Kunz, C. Borghouts, C. Buerger, and B. Groner Peptide Aptamers with Binding Specificity for the Intracellular Domain of the ErbB2 Receptor Interfere with AKT Signaling and Sensitize Breast Cancer Cells to Taxol Mol. Cancer Res., December 1, 2006; 4(12): 983 - 998. [Abstract] [Full Text] [PDF]

				C. R. Ireson and L. R. Kelland Discovery and development of anticancer aptamers Mol. Cancer Ther., December 1, 2006; 5(12): 2957 - 2962. [Abstract] [Full Text] [PDF]

				B. M. Zhao and F. M. Hoffmann Inhibition of Transforming Growth Factor-beta1-induced Signaling and Epithelial-to-Mesenchymal Transition by the Smad-binding Peptide Aptamer Trx-SARA Mol. Biol. Cell, September 1, 2006; 17(9): 3819 - 3831. [Abstract] [Full Text] [PDF]

				E. Tomai, K. Butz, C. Lohrey, F. von Weizsacker, H. Zentgraf, and F. Hoppe-Seyler Peptide Aptamer-mediated Inhibition of Target Proteins by Sequestration into Aggresomes J. Biol. Chem., July 28, 2006; 281(30): 21345 - 21352. [Abstract] [Full Text] [PDF]

				L. Lopez-Ochoa, J. Ramirez-Prado, and L. Hanley-Bowdoin Peptide Aptamers That Bind to a Geminivirus Replication Protein Interfere with Viral Replication in Plant Cells. J. Virol., June 1, 2006; 80(12): 5841 - 5853. [Abstract] [Full Text] [PDF]

				M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci Interleukin-6 in aging and chronic disease: a magnificent pathway. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 575 - 584. [Abstract] [Full Text] [PDF]

				E. Heck, D. Lengenfelder, M. Schmidt, I. Muller-Fleckenstein, B. Fleckenstein, B. Biesinger, and A. Ensser T-Cell Growth Transformation by Herpesvirus Saimiri Is Independent of STAT3 Activation J. Virol., May 1, 2005; 79(9): 5713 - 5720. [Abstract] [Full Text] [PDF]